Abbott began enrolling U.S. patients in the EXCEL trial, which will compare the use of the Xience Prime or Xience V drug-eluting strents to coronary artery bypass graft (CABG) surgery for effectiveness of left main revascularization. The large-scale trial will attempt to show stenting has comparable or superior outcomes to CABG, which has long been the dream of interventional cardiology.
